These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 31190000

  • 21. Comparative Pathologic Analysis of Breast Cancers Classified as HER2/neu-Amplified by FISH Using a Standard HER2/CEP17 Dual Probe and an Alternative Chromosome 17 Control Probe.
    Zare S, Lin L, Alghamdi AG, Daehne S, Roma AA, Hasteh F, Dell'Aquila M, Fadare O.
    Am J Surg Pathol; 2018 Sep; 42(9):1208-1215. PubMed ID: 29923906
    [Abstract] [Full Text] [Related]

  • 22. Impact of the 2013 ASCO/CAP HER2 Guideline Updates at an Academic Medical Center That Performs Primary HER2 FISH Testing: Increase in Equivocal Results and Utility of Reflex Immunohistochemistry.
    Muller KE, Marotti JD, Memoli VA, Wells WA, Tafe LJ.
    Am J Clin Pathol; 2015 Aug; 144(2):247-52. PubMed ID: 26185309
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Well-differentiated invasive breast cancers with equivocal HER2 immunohistochemistry: what is the yield of routine reflex in-situ hybridization testing?
    Bethune GC, Pettit AS, Veldhuijzen van Zanten D, Barnes PJ.
    Histopathology; 2017 May; 70(6):966-974. PubMed ID: 28032917
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer.
    Guo L, Yuan P, Zhang J, Ling Y, Li W, Zhao B, Ying J, Xuan L.
    Breast Cancer Res Treat; 2017 Nov; 166(1):77-84. PubMed ID: 28712009
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Impact of updated HER2 testing guidelines in breast cancer--re-evaluation of HERA trial fluorescence in situ hybridization data.
    Stoss OC, Scheel A, Nagelmeier I, Schildhaus HU, Henkel T, Viale G, Jasani B, Untch M, Rüschoff J.
    Mod Pathol; 2015 Dec; 28(12):1528-34. PubMed ID: 26403781
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Intrinsic molecular subtypes of breast cancers categorized as HER2-positive using an alternative chromosome 17 probe assay.
    Desai NV, Torous V, Parker J, Auman JT, Rosson GB, Cruz C, Perou CM, Schnitt SJ, Tung N.
    Breast Cancer Res; 2018 Jul 11; 20(1):75. PubMed ID: 29996866
    [Abstract] [Full Text] [Related]

  • 32. Impact of 2013 ASCO/CAP guidelines on HER2 determination of invasive breast cancer: A single institution experience using frontline dual-color FISH.
    Ragazzi M, Bisagni A, Gasparini E, Kuhn E, Bassano C, Tamagnini I, Foroni M, Bortesi M, Falco G, Ferrari G, Braglia L, Savoldi L, Bologna A, Di Cicilia R, Bisagni G, Gardini G.
    Breast; 2017 Aug 11; 34():65-72. PubMed ID: 28521178
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Assessment of HER2 using the 2018 ASCO/CAP guideline update for invasive breast cancer: a critical look at cases classified as HER2 2+ by immunohistochemistry.
    Taylor VJ, Barnes PJ, Godwin SC, Bethune GC.
    Virchows Arch; 2021 Jul 11; 479(1):23-31. PubMed ID: 33527151
    [Abstract] [Full Text] [Related]

  • 36. HER2 equivocal breast cancer that is positive by alternative probe HER2 FISH are classified as HER2 negative by Oncotype DX.
    Tozbikian GH, Zynger DL.
    Breast J; 2018 Jul 11; 24(4):535-540. PubMed ID: 29498449
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Cost-effectiveness of a Dual (Immunohistochemistry and Fluorescence In Situ Hybridization) HER2/neu Testing Strategy on Invasive Breast Cancers.
    Hariri N, Zare S, Murphy J, Fadare O.
    Appl Immunohistochem Mol Morphol; 2021 Jan 11; 29(1):42-48. PubMed ID: 32205742
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.